血液肾损伤分子-1与中性粒细胞明胶酶相关脂质运载蛋白水平与慢性肾脏病进展至终末期肾病的关联
在1982例3-5期非透析慢性肾脏病患者中,基线血浆肾损伤分子-1和中性粒细胞明胶酶相关脂质运载蛋白每升高1个标准差,与终末期肾病风险独立相关(HR分别为1.25和1.35),但与心血管事件或死亡无关联,且未改善模型判别或风险重分类。
要点
- 血浆肾损伤分子-1每升高1个标准差,终末期肾病风险HR为1.25(95%CI 1.10-1.43,P<0.001)。
- 血浆中性粒细胞明胶酶相关脂质运载蛋白每升高1个标准差,终末期肾病风险HR为1.35(95%CI 1.14-1.59,P≤0.001)。
- 两标志物与心血管事件或死亡无关联,加入传统模型未显著改善判别或重分类。
核心结论
- 在中重度慢性肾脏病患者中,血浆肾损伤分子-1和中性粒细胞明胶酶相关脂质运载蛋白水平是进展至终末期肾病的独立危险因素。
- 需要进一步研究以确定这些新型生物标志物在临床环境中的效用和成本效益。
研究设计与样本
- 研究纳入2002年6月初至2013年6月初招募于慢性肾功能不全标准实施研究的1982例成人全因非透析依赖慢性肾脏病3-5期患者。
- 在基线血浆样本中测量肾损伤分子-1和中性粒细胞明胶酶相关脂质运载蛋白,采用Cox回归模型、受试者工作特征曲线分析和重分类统计分析与研究终点的关联。
主要发现
- 中位随访29.5个月(四分位距14.9-53.5)期间,21.6%的患者进展至终末期肾病,27%死亡,6.6%发生主要不良心血管事件。
- 血浆肾损伤分子-1每升高1个标准差,终末期肾病风险HR为1.25(95%CI 1.10-1.43,P<0.001)。
- 血浆中性粒细胞明胶酶相关脂质运载蛋白每升高1个标准差,终末期肾病风险HR为1.35(95%CI 1.14-1.59,P≤0.001)。
- 两标志物与心血管事件或死亡风险无关联。
- 将生物标志物加入基于传统临床特征和实验室参数的基线风险模型,未显著改善模型判别或风险重分类。
关键数值与推荐
- 血浆肾损伤分子-1每升高1个标准差,终末期肾病风险HR为1.25(95%CI 1.10-1.43,P<0.001)。
- 血浆中性粒细胞明胶酶相关脂质运载蛋白每升高1个标准差,终末期肾病风险HR为1.35(95%CI 1.14-1.59,P≤0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要进一步研究以确定这些新型生物标志物在临床环境中的效用和成本效益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Elevated levels of urinary kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin are associated with negative outcomes in CKD. Our study aimed to explore the prognostic accuracy of blood levels of kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin for progression to ESRD, major adverse cardiovascular events, and death in a large cohort of adult patients with all-cause nondialysis-dependent CKD stages 3-5. We considered whether these factors improve prediction in relation to traditional biomarkers and clinical parameters. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin were measured on baseline plasma samples from 1982 patients who were recruited to the Chronic Renal Insufficiency Standards Implementation Study between the start of June of 2002 and the start of June of 2013. Associations with study end points were assessed using Cox regression models, receiver operator characteristic curve analyses, and reclassification statistics. RESULTS: Over a median follow-up of 29.5 months (interquartile range, 14.9-53.5), 21.6% of patients progressed to ESRD, 27% died, and 6.6% suffered a major adverse cardiovascular event. Higher blood levels of kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin were independently associated with a greater risk for ESRD (hazard ratio, 1.25; 95% confidence interval, 1.10 to 1.43; P<0.001 and hazard ratio, 1.35; 95% confidence interval, 1.14 to 1.59; P≤0.001, respectively, per 1 SD higher biomarker concentration). There was no association with risk for cardiovascular events or death. The addition of biomarkers to our baseline risk model of traditional clinical characteristics and laboratory parameters did not significantly improve model discrimination or risk reclassification. CONCLUSIONS: In patients with moderate to severe CKD, kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin blood levels are independent risk factors for progression to ESRD. Additional studies are needed to establish the utility and cost-effectiveness of these novel biomarkers in the clinical setting.
引用
- Alderson HV, Ritchie JP, Pagano S, et al. The Associations of Blood Kidney Injury Molecule-1 and Neutrophil Gelatinase-Associated Lipocalin with Progression from CKD to ESRD. Clin J Am Soc Nephrol. 2016. PMID: 27852662. doi:10.2215/CJN.02670316
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。